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Research
AbstrACt
Objectives We compared the effectiveness of an intensive 
smoking cessation intervention among smokers with and 
without a severe mental disorder (SMD) and identified 
factors associated with successful quitting. The main 
hypothesis was that smokers with an SMD would be less 
likely to stay continuously smoke-free for 6 months.
Design A prospective cohort study.
setting In all, 302 smoking cessation clinics in Denmark 
from municipal clinics, pharmacies, hospitals, midwives, 
primary care facilities and other private providers who 
reported data to the national Danish Smoking Cessation 
Database from 2006 to 2016 participated in this study.
Participants A total of 38 293 patients from the Danish 
Smoking Cessation Database. Patients with an SMD 
were identified by linking data to the Danish National 
Patient Register. Diagnoses of organic mental disorders 
(F0 chapter) or intellectual disabilities (F7 chapter) were 
not included. Smokers ≥18 years old who were attending 
a Gold Standard Programme (GSP) with planned follow-
up were included. Smokers not wanting contact after 6 
months were excluded.
Interventions A comprehensive manual-based smoking 
cessation intervention comprising five meetings over a 
6-week period (the GSP).
Main outcome measures Self-reported continuous 
abstinence at the 6-month follow-up.
results In all, 69% of the participants participated 
in the follow-up after 6 months. The overall rate of 
successful quitting was high but significantly lower in 
SMD smokers (29% vs 38%; OR 0.74; 95% CI 0.68 to 
0.80). Variables associated with successful quitting were 
compliance (defined as attending ≥75% of the planned 
meetings), older age and male gender as well as not being 
disadvantaged, heavy smoking or recommendation of 
intervention by health professionals.
Conclusions Only 29% of smokers with an SMD 
successfully quit smoking which was significantly lower 
than the 38% of smokers without an SMD. Compliance 
was the most important predictor for successful quitting.
IntrODuCtIOn 
The prevalence of smoking among patients 
with mental illness is relatively high.1 2 A 
Danish survey showed that 39% of patients 
with a mental illness were daily smokers 
compared with 20% of the general popu-
lation.3 Furthermore, patients with mental 
illness were 2.5 times more likely to be heavy 
smokers.3 Overall, patients with a severe 
mental illness had reduced life expectan-
cies of 15 and 20 years in women and men, 
respectively,4 and a recent study found that 
one-third of the 15 lost life years in smokers 
with a severe mental disorder (SMD) may 
be attributed to smoking.2 Based on obser-
vational studies, successful smoking cessa-
tion has been shown to improve mental 
health5 and reduce mortality and morbidity 
in patients with psychiatric issues.2 6 Most 
smoking cessation interventions combine 
behavioural and pharmacological support. 
A recent review on the efficacy of smoking 
cessation intervention in patients with a 
severe mental illness concluded that bupro-
pion and varenicline appear to be as effective 
in populations with psychiatric issues as in the 
strengths and limitations of this study
 ► This was a prospective cohort study based on 
38 293 smokers with or without mental disorder(s).
 ► Quit rates at the 6-month follow-up were based on 
unvalidated self-reporting.
 ► When identifying smokers with psychiatric issues 
in this study, only smokers with a mental disorder 
severe enough to justify hospitalisation (inpatient 
or outpatient) were recognised. This cohort might 
contain patients with less severe mental disor-
der(s)  (SMD/SMDs), who (in this study) were cate-
gorised as smokers without SMD.
 ► Participants with an SMD were included indepen-
dent of the time span from diagnoses to intervention 
onset.
 ► This study was based on routinely collected health 
data, but because the aim of this study was in 
line with the purposes of the Smoking Cessation 
Database, we considered the implications minimal.
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general public.7 However, the effectiveness of behavioural 
interventions alone remains unclear.7 Despite these find-
ings, smoking is often ignored in inpatient psychiatry.8 
In 2013, the National Institute for Health and Care 
Excellence published a guideline concerning smoking 
cessation for individuals requiring acute, maternity and 
mental health services, stating that smokers with a mental 
illness should be offered intensive smoking cessation 
support.9 The Gold Standard Programme (GSP) is an 
intensive face-to-face smoking cessation intervention 
consisting of 5–6 meetings. The programme has been 
shown to have a good effect on smoking cessation in 
other subpopulations, as well as for the general popu-
lation,10–14 but its effectiveness in smokers with an SMD 
remains unknown.
The aim of this study was to compare the effectiveness 
of the GSP in smokers with and without a diagnosed SMD 
and to identify factors associated with successful quitting. 
We hypothesised that this vulnerable subgroup of smokers 
would be less likely to be continuously smoke-free after 
6 months than smokers without a mental disorder.
MethOD
study design and setting
We performed a register-based cohort study using data 
from two national Danish registers: the Smoking Cessa-
tion Database15 and the National Patient Register.16 17 The 
Smoking Cessation Database was established to evaluate 
the effect of smoking cessation interventions offered 
throughout Denmark, and data has been prospectively 
collected since 2001. The database now includes >111 000 
smokers who received face-to-face assistance to quit 
smoking.
At birth or on immigration, all people in Denmark are 
assigned a unique personal 10-digit identification number 
known as a ‘Central Person Register’ (CPR) number 
which contains information on sex and date of birth of 
the individual.18 The CPR number is used as the unique 
identification number in the National Patient Register as 
well as in many other Danish registers, making it possible 
to link information relating to an individual.19
Since 2006, each smoker provided informed consent 
and was thereafter registered in the Smoking Cessation 
Database with their CPR number. The CPR number was 
used to control for smokers attending more than one 
intervention and to identify smokers diagnosed with 
mental disorder(s) using data from the National Patient 
Register. Since 1995, all contacts (inpatient or outpa-
tient) with somatic and psychiatric wards of all hospitals 
in Denmark have been registered in the National Patient 
Register using the International Classification of Diseases, 
10th edition.16 17
All smokers in Denmark, including smokers with a 
mental disorder, have access to smoking cessation inter-
ventions without referral and free of charge. Throughout 
the study period from 1 January 2006 to 31 December 
2016, 302 smoking cessation clinics in different settings, 
such as hospitals, midwife interactions, municipal clinics, 
pharmacies, primary care facilities and other private 
institutions, reported data to the Smoking Cessation 
Database.15 Approximately 80%–90% of the face-to-face 
interventions in Denmark are registered in the Smoking 
Cessation Database, and are considered a representative 
sample.20
In Denmark, the prevalence of daily smokers (≥15 
years) dropped from 25% in 2006 to 16% in 2016.21 This 
corresponds to a drop from 1 100 000 to 765 000 smokers. 
Thus, the Smoking Cessation Database (SCDB) contains 
information on 6%–9% of the daily smokers in Denmark.
Intervention
GSP is the standard smoking cessation intervention 
in Denmark.15 The GSP comprises five meetings held 
either in groups (2 hours/session) or as an individual 
session (first session lasting 40 min and approximately 
20 min/sessions thereafter) over a 6-week period. The 
programme was presented by specially trained staff and 
was counselling-based with a clearly structured manu-
al-based patient education programme. The quit date was 
planned between the second and the third meeting. Each 
smoker was offered individual counselling on nicotine 
replacement therapy or other medical support according 
to their level of dependence, as measured by the Fager-
ström test score.15 22 It was recommended (but not 
mandatory) after 3 months to offer a sixth meeting after 
3 months focusing on relapse prevention. To follow-up 
on the effect of the intervention, patients registered 
in the Smoking Cessation Database were contacted by 
phone 6 months (±1 month) after the planned quit date 
and asked about their smoking status.15 Because patients 
were reached by phone, the self-reported smoking status 
was not validated.15 The intervention has been previously 
described in detail.10 14 15
Participants
The study cohort included 74 121 smokers registered in 
the Smoking Cessation Database during the study period. 
If a smoker attended more than one intervention, only 
the latest intervention was included (7180 smokers 
(corresponding to 9.3% of all smokers) were registered 
more than once; 9523 interventions were not included). 
Smokers were not included in the study if they met any of 
the following criteria: younger than 18 years of age at the 
onset of the intervention (1146), no attendance at a GSP 
(16 077) or attendance at a smoking cessation clinic that 
predecided, on the administrative level, not to contact 
their participants for follow-up after 6 months (8496).
To identify smokers with a mental disorder(s), the 
remaining 38 879 smokers in the Smoking Cessation Data-
base were cross-referenced with data from the National 
Patient Register using CPR numbers. Psychiatric discharge 
diagnoses given before the onset of the smoking cessation 
intervention were extracted. All psychiatric diagnoses 
(Chapter V; Mental and behavioural disorders, F00-F99), except 
F17 (Mental and behavioural disorders due to use of tobacco) 
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were initially linked to the smokers. Patients diagnosed 
with organic mental disorders (F0 chapter) or intellectual 
disabilities (F7 chapter) were not included in the study 
regardless of other psychiatric diagnoses. Smokers without 
any psychiatric diagnosis composed the control group. 
Patients were categorised based on the severity and occur-
rence of a specific SMD according to the following hier-
archy: schizophrenia (F20), schizotypal disorder (F21), 
other psychoses (F22-F25, F28-29), manic episodes (F30), 
bipolar disorder (F31), depression (F32-F34), anxiety 
(F40-F41), obsessive-compulsive disorder (F42), post-trau-
matic stress disorder (F43.1), personality disorders (F60-
F69) and substance use disorder (SUD) (F1). To avoid 
representing a patient multiple times in the analyses, the 
most severe diagnosis as defined by the hierarchy above 
was considered the primary discharge diagnosis. Smokers 
without an SMD but with other diagnosed mental disor-
ders were omitted from the primary outcome analysis. 
Thus, 38 293 smokers with or without a mental disorder 
were included in this study (see flow chart in figure 1).
Patient and public involvement
This study is based on data from any smokers partici-
pating in smoking cessation interventions available to 
the public without referral and free of charge. Patients or 
public were not otherwise involved in this study.
Outcome and other variables
The primary outcome was self-reported continuous absti-
nence measured 6 months after quitting. Continuous 
abstinence was defined as not having smoked at all from 
the quit date to the 6-month follow-up contact.15
Figure 1 Flow chart of patient inclusion in the study. Smokers at least 18 years of age who attended a GSP between 1 January 
2006 and 31 December 2016 were included in this study. A total of 11 534 smokers were lost to follow-up, leaving 25 411 
smokers for inclusion in the outcome analyses. GSP, Gold Standard Programme; NPR, National Patient Register. 
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For each smoker registered in the Smoking Cessation 
Database, data relating to sociodemographic charac-
teristics, smoking history, intervention programme and 
follow-up information were collected. Age and smoking 
information were collected as continuous variables, 
whereas the remaining variables were categorical and 
grouped as shown in table 1 (and online supplementary 
appendix A). Confounders and predictors included in 
the statistical analyses are listed in table 1.
Compliance with regard to meeting adherence was 
defined as attending at least 75% of the scheduled meet-
ings as defined by the steering committee.23
Smokers were considered heavy smokers if they fulfilled 
one or more of three criteria: a ≥20 pack-year smoking 
history, daily consumption of ≥20 cigarettes or a nico-
tine dependency ≥7 points according to the Fagerström 
test score.13 22 Smokers were considered disadvantaged if 
they fulfilled at least one of two criteria: unemployment 
(receiving unemployment benefits) or low level of educa-
tion (no education except for elementary school or short 
work-related courses).14
Data access and cleaning
We had full access to data relating to all smokers recorded 
in the Smoking Cessation Database from 2006 to 2016. 
Throughout this period, smokers were registered using 
their individual CPR number. All CPR numbers were 
checked for validity using official validation rules. Invalid 
numbers were checked in the Civil Registration System 
and corrected if possible, and age and sex were corrected 
accordingly. If correction was not possible, the smokers 
were excluded from the database. In this study, 484 of 
67 339 smokers (corresponding to 0.7%) were omitted 
from the database due to an invalid CPR number.
The online registration application of the Smoking 
Cessation Database supplies automatic data validation 
rules to ensure that only valid dates and required data 
are entered. In addition to these rules, daily consumption 
of tobacco was manually checked. Daily consumption of 
more than 100 g was considered unlikely, and these data 
were recoded to ‘missing’. Likewise, years of smoking was 
recoded to ‘missing’ if the years of smoking were greater 
than the age of the smoker.
statistical analysis
After performing initial analyses on the selected predic-
tors (from online supplementary appendix A) adjusted 
for sex and age, a multivariable mixed-effect model was 
fitted to test for differences in continuous abstinence. The 
predictors were chosen based on the initial analysis and 
established knowledge.24 The multivariable analysis was 
performed by entering all the predictors together (see 
table 1). In addition, the analysis was adjusted for hier-
archical clustering using the different smoking cessation 
clinics as the 1st level cluster. The analysis was repeated 
for relevant subgroups of mental disorders. To examine 
whether the time span from diagnosis to participation in 
a GSP was related to continuous abstinence, a separate 
univariate logistical regression was conducted. The span 
was calculated as time from initial diagnosis of an SMD to 
the start of the GSP.
Data were reported according to the REporting 
of studies Conducted using Observational Routinely 
collected health Data statement.25 Patients with missing 
values were excluded from the analyses. The results were 
presented as ORs and 95% CIs. Non-respondent analysis 
was performed using a χ2 test to compare respondents 
to non-respondents. A similar analysis was performed 
to compare the smokers who were intentionally not 
followed up to the included smokers. A two-sided p value 
<0.05 was considered statistically significant. All statis-
tical calculations were performed with Stata/IC V.15.0 
(StataCorp).
results
In this cohort study, 38 293 smokers were linked to the 
National Patient Register to identify smokers with a 
mental disorder. While 25 411 smokers with or without an 
SMD were included in the main analysis, 31% were lost to 
follow-up (29% among smokers without a mental illness 
and 39% among smokers with an SMD) (see  figure 1). 
Non-respondent analyses revealed that except for living 
with a smoker, all other tested predictors significantly 
differed between the respondents and the non-respon-
dents. The largest difference (14 percentage points) 
observed was in participant compliance with the respon-
dents showing more compliance with the programme. 
Smokers with an SMD were more likely to withdraw from 
the study (schizophrenia spectrum, 43.2%; affective disor-
ders, 38.9%; anxiety, 36.1%; personality disorders, 38.7%; 
SUD, 36.7%) as were women, disadvantaged smokers and 
smokers who attended individual counselling; however, 
heavy smokers and smokers who were recommended to 
quit by healthcare staff were more likely to be respondents.
The percentage of individuals who successfully quit was 
29.4% and 38% for smokers with an SMD and the control 
group, respectively (see table 2).
The characteristics of smokers without a mental 
disorder and smokers with an SMD differed considerably 
(see table 1, and online supplementary appendix A). In 
particular, the proportion of smokers with an SMD was 
highest among young smokers and gradually decreased 
as age increased. In addition, smokers with an SMD were 
more likely to be heavy smokers, non-compliant and 
recommended to stop smoking by healthcare staff and 
were more often disadvantaged; all these factors were 
predictors of relapsing within 6 months of completing 
the GSP. In addition, smokers with an SMD were less 
likely to live with other smokers and more likely to attend 
individual interventions, both of which were predictors 
of a successful outcome. Approximately half the smokers 
in both groups (51% of smokers with an SMD and 45% 
without an SMD) were offered pharmaceutical support 
(eg, nicotine replacement therapy, varenicline or bupro-
pion, free of charge).
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Table 1 Characteristics of the study population and predictors for continuous abstinence
Characteristics OR for successful quitting
Control, n (%) SMD, n (%)
Initial analyses
OR (95% CI)
Multivariate 
analyses
OR (95% CI)
Adjusted for
cluster
Smokers with a mental
disorder
  No mental disorder 29 783 (80.6) 1 1
  Yes, SMD 7162 (19.4) 0.68 (0.63 to 0.73)* 0.74 (0.68 to 0.80)*
Participants
Age (years)
  18–24 1304 (4.4) 389 (5.4) 1 1
  25–34 3423 (11.5) 1064 (14.9) 1.50 (1.27 to 1.78)* 1.33 (1.10 to 1.61)*
  35–44 5661 (19) 1388 (19.4) 1.54 (1.31 to 1.81)* 1.37 (1.14 to 1.64)*
  45–54 7579 (25.5) 1877 (26.2) 1.59 (1.36 to 1.87)* 1.47 (1.23 to 1.76)*
  55–64 7098 (23.8) 1668 (23.3) 1.70 (1.45 to 1.99)* 1.53 (1.28 to 1.84)*
  65+ 4718 (15.8) 776 (10.8) 1.61 (1.37 to 1.90)* 1.30 (1.07 to 0.57)*
Sex
  Men 12 278 (41.2) 2937 (41) 1 1
  Women 17 505 (58.8) 4225 (59) 0.87 (0.83 to 0.92)* 0.85 (0.80 to 0.90)*
Disadvantaged smoker†
  No 18 451 (62) 2746 (38.3) 1 1
  Yes 10 178 (34.2) 4128 (57.6) 0.79 (0.74 to 0.83)* 0.84 (0.79 to 0.89)*
Heavy smoker‡
  No 7032 (23.6) 1243 (17.4) 1 1
  Yes 22 044 (74) 5770 (80.6) 0.69 (0.64 to 0.73)* 0.74 (0.69 to 0.80)*
Compliance with programme§
  No 10 661 (35.8) 3393 (47.4) 1 1
  Yes 18 712 (62.8) 3684 (51.4) 3.32 (3.12 to 3.53)* 3.26 (3.05 to 3.48)*
Living with a smoker
  No 19 389 (65.1) 5168 (72.2) 1 1
  Yes 10 129 (34) 1917 (26.8) 0.90 (0.86 to 0.96)* 0.90 (0.85 to 0.96)*
Earlier quit attempts
  No 11 227 (37.7) 2985 (41.7) 1 1
  Yes 17 966 (60.3) 4001 (55.9) 1.09 (1.04 to 1.15)* 1.03 (0.98 to 1.10)
Recommendation by healthcare 
staff¶
  No 11 322 (38) 2162 (30.2) 1 1
  Yes 17 078 (57.3) 4690 (65.5) 0.86 (0.81 to 0.91)* 0.89 (0.84 to 0.95) *
Smoking cessation clinic
Setting
  Municipality 22 653 (76.1) 5636 (78.7) 1 1
  Pharmacy 4522 (15.2) 938 (13.1) 1.06 (0.98 to 1.13) 1.02 (0.90 to 1.15)
  Hospital (including midwives) 1943 (6.5) 514 (7.2) 1.02 (0.92 to 1.13) 1.13 (0.94 to 1.36)
  Other 665 (2.2) 74 (1) 0.99 (0.83 to 1.20) 1.05 (0.81 to 1.38)
Continued
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Primary outcome: smoking cessation at 6 months
After adjusting for clustering and confounding factors, 
we found that smokers with an SMD were significantly less 
likely to maintain continuous abstinence 6 months after 
attending a GSP (OR 0.74, 95% CI 0.68 to 0.80; p<0.001). 
The time span between the primary discharge diagnosis 
and the start of the GSP showed a small but statistically 
significant association with continuous abstinence (OR 
1.02, 95% CI 1.00 to 1.03; p=0.013). We identified asso-
ciations between a higher risk of relapse and female 
gender (OR 0.85, 95% CI 0.80 to 0.90), disadvantaged 
status (OR 0.84, 95% CI 0.79 to 0.89), heavy smoking 
(OR 0.74, 95% CI 0.69 to 0.80) and recommendations to 
quit by healthcare staff (OR 0.89, 95% CI 0.84 to 0.95). 
Factors associated with successful quitting were older age 
(OR 1.30, 95% CI 1.07 to 1.57) compliance with the GSP 
(OR 3.26, 95% CI 3.05 to 3.48) and attendance of an indi-
vidual intervention (OR 1.17, 95% CI 1.07 to 1.28).
The proportion of successful quitters was 38% in the 
control group versus 30% in patients with any mental 
disorder (see table 2). The quit rates among the SMD 
subgroups differed by approximately 7 percentage points; 
Characteristics OR for successful quitting
Control, n (%) SMD, n (%)
Initial analyses
OR (95% CI)
Multivariate 
analyses
OR (95% CI)
Adjusted for
cluster
Smoking cessation 
intervention
Programme format
  Group 24 925 (83.7) 5347 (74.7) 1 1
  Individual 4858 (16.3) 1813 (25.3) 1.30 (1.21 to 1.39)* 1.17 (1.07 to 1.28)*
Cluster
Smoking cessation clinic 0.05 (0.03 to 0.08)*
The initial analyses were adjusted for sex and age only. In addition  to  the listed predictors, the multivariable model was adjusted for the year 
of intervention and hierarchical clustering (smoking cessation clinic). 
The results were reported as ORs and 95% CIs.
*P value <0.05 (considered statistically significant).
†Disadvantaged: ≤12 years of school and/or unemployed.
‡Heavy smoker: ≥20 pack years, Fagerström score of ≥7 points and/or daily consumption of ≥20 cigarettes.
§Compliance: attended ≥75% of the planned meeting sessions.
¶Healthcare staff: doctors, nurses, nurses’ assistants, midwives, etc.
SMD, severe mental disorder.
Table 1 Continued 
Table 2 Crude quit rates and associations of successful quitting according to smoker subgroups stratified by the severity of 
the mental disorder
Diagnoses (ICD-10) n
Crude quit rate
Multivariate analyses
OR (95% CI)
P values% Adjusted for cluster
Control: no psychiatric diagnoses 21 044 38 1
Any mental disorder 5306 30 0.75 (0.70 to 0.81)* <0.000
Severe mental disorder 4404 29.4 0.74 (0.68 to 0.80)* <0.000
Schizophrenia spectrum (F20-F29) 692 25.7 0.61 (0.50 to 0.74)* <0.000
Affective disorders (F30-F34) 1742 31 0.80 (0.71 to 0.90)* <0.000
Anxiety (F40-F42, F43.1) 548 31.9 0.86 (0.70 to 1.06) 0.156
Personality disorders (F60-69) 294 26.9 0.62 (0.46 to 0.83)* 0.001
Substance use disorder (F10-16, 
F18-F19)
1128 28.6 0.68 (0.59 to 0.79)* <0.000
Other 902 32.9 0.83 (0.71 to 0.98)* 0.027
*P <0.05. 
ICD-10, International Classification of Diseases, 10th edition.
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however, for patients within the schizophrenia spectrum, 
which was the least successful group, the proportion of 
successful quitters was 25.7%. All the subgroups, except 
anxiety, were significantly less likely to stay continuously 
abstinent after 6 months than the control group.
We examined the occurrence of dual diagnoses, defined 
as having SUD in addition to any other mental disorder(s), 
and the effect of these diagnoses on smoking cessation for 
subgroups of smokers with a mental disorder. The occur-
rence of dual diagnoses differed between 17% and 41% 
in the subgroups. Moreover, the proportion of successful 
quitters was lower in patients with dual diagnoses (18.9%–
26.9%) than in patients without SUD (27.7%–33.9%), 
corresponding to a reduction in successful outcomes by 
18%–43%. This should be compared with a quit rate of 
30.5% among patients with SUD alone (see figure 2).
Intentional lack of follow-up
The characteristics shown in table 1 were compared 
between the included smokers and smokers who were 
intentionally not followed up due to an administrative 
decision in the smoking cessation clinic. The analyses 
showed that there were statistically significant differences 
between the two groups with regard to mental diagnoses, 
heavy smoking, compliance, living with a smoker, earlier 
quit attempts, setting, programme format and year of 
intervention. The differences were most pronounced in 
relation to arena (22 percentage points), where smokers 
attending an intervention in a municipal clinic were most 
likely to receive a follow-up call. The year of intervention 
(9 percentage points) revealed that smokers were less 
likely to receive follow-up before 2010. All other factors 
differed by fewer than 5 percentage points, and smokers 
with a mental disorder were more likely to receive 
follow-up than heavy smokers, non-compliant smokers, 
smokers not living with another smoker and smokers 
attending a group intervention.
DIsCussIOn
Overall, 28% of the smokers with an SMD stayed contin-
uously smoke-free for at least 6 months after undergoing 
a GSP intervention compared with 38% without an 
SMD. This was in agreement with our main hypothesis. 
Compliance was by far the most important predictor of a 
successful outcome. Dual diagnoses of SMDs lowered the 
proportion of successful quitters to 19%–27%, depending 
on the diagnoses.
Smokers with an SMD were as likely to want to quit 
smoking as the general population,3 but the evidence of 
smoking cessation intervention is sparse among this group. 
A recent review concluded that although bupropion and 
varenicline appear to be effective among smokers with an 
SMD, the efficacy of nicotine replacement therapy and 
behavioural treatment is still unclear.7 Another review 
illuminating the effect of specialised advice to smokers 
with an SMD revealed only one ongoing trial investigating 
this topic.26
Promising results were presented in a randomised trial 
on treating tobacco dependence among inpatients at a 
psychiatric ward with a complete smoking ban. Prochaska 
et al observed a point prevalence of 14% in smokers 
undergoing an intervention combining behavioural treat-
ment and nicotine patches at 6 months after intervention 
in contrast to 7% in the usual care control group.8 Even 
unmotivated patients were able to successfully quit, and 
the long-term results after 18 months were positive.8
In our study, 28% of the participants with an SMD 
continued to abstain after 6 months. Smokers diagnosed 
within the schizophrenia spectrum benefited the least 
from the GSP. Although meta-analyses have also shown 
a lower effect in this group,27 smokers with depres-
sion showed higher quit rates.28 A review reported that 
only two small studies have been published concerning 
smokers with bipolar disorders,29 and both trials had diffi-
culties recruiting smokers within this subgroup. In our 
Figure 2 Crude quit rates according to the specified mental disorder with or without SUD. SUD, substance use disorder.
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subgroup analysis, smokers with anxiety (F4 Chapter) 
were also likely to have been slightly underpowered which 
was also the case for the subgroup of smokers classified as 
‘other diagnoses’.
The GSP is a package consisting of several elements, 
including an extensive patient education programme, 
individual counselling and pharmaceutical support.10 15 In 
our study, it was not possible to pinpoint which elements 
were the most important or whether some of the elements 
were unnecessary for different groups of smokers. In 
addition to the different mental diagnoses, variations in 
the severity of mental disease may impact the quit rates. 
On the one hand, one could expect that smokers with an 
SMD are more likely to be successful in their quit attempt 
when they are well treated and close to discharge. On 
the other hand, a hospital stay in completely smoke-free 
surroundings has been shown to be supportive—for SMD 
smokers as well.8
Dual diagnoses appear to have a great impact on 
the ability to quit smoking, and it would be relevant to 
evaluate combined interventions for both smoking and 
substance abuse. Although the evidence is also sparse, 
smoking cessation intervention has been shown to be 
effective for smokers in short-term substance abuse 
treatment.30
This study has strengths and limitations. Because the 
aim of this study was in line with the purposes of the 
Smoking Cessation Database, we considered the impli-
cations of using these routinely collected health data to 
be minimal. However, one potential weakness was that 
participants with an SMD were included independent 
of the time span from diagnoses to the intervention 
onset. Surprisingly, we found only a small significant 
association between time span and continuous absti-
nence, and this association should be investigated in 
more detail in future intervention studies. Using the 
National Patient Register, we identified only smokers 
with a mental disorder severe enough to justify hospi-
talisation (inpatient or outpatient). There might be 
patients in the Smoking Cessation Database with mental 
disorders who did not receive hospital care, but we 
must assume that their mental disorders are much less 
severe. The proportion of participants lost to follow-up 
was moderate (31%). In this study, we only included 
respondents in the final analysis, thus assuming that 
the quit rates among non-respondents were similar 
to the quit rates estimated in this study. Because the 
non-respondent analysis showed a higher proportion 
of non-compliant participants among the non-respon-
dents, it is likely that the quit rates in this study are 
overestimated.
One strength of this study was the large nationwide 
cohort and the inclusion of all settings (municipalities, 
hospitals, pharmacies, etc) where smoking cessation 
interventions in Denmark were conducted. Data from 
both registries used in this study provide a high degree of 
completeness and precision, and the amount of missing 
data was very low.15 17 We were unable to identify possible 
misclassifications, but the occurrence of these was 
expected to be very low.15 17
The use of continuous abstinence instead of point preva-
lence was a strength, but self-reporting without biomarker 
validation was a limitation31 that might have introduced 
reporting bias.32 Contrary to the logical presumption 
that the use of this outcome would prove more precise, a 
Canadian study showed no significant difference between 
self-reported smoking status and urinary cotinine levels.33 
The use of carbon monoxide tests to validate smoking 
status showed that validation increased the detection of 
smokers with short-term and long-term quit rates by only 
6 and 3 percentage points, respectively.34 35 Similar results 
were observed in a Danish study where self-reported and 
validated abstinence differed by 3–4 percentage points.36
Due to differences in national and cultural traditions, 
smoking habits, socioeconomic conditions and the diag-
nosis of SMDs, the external validity of these results is 
limited and should be considered carefully before extrap-
olating to other developed countries.
Overall, it is important for smokers with a mental 
disorder to be offered clinical help to quit smoking due 
to the many positive effects of smoking cessation on 
both physical and mental health.5 However, the evidence 
on how to best help this group of smokers is sparse. 
Randomised controlled trials have shown that smoking 
cessation interventions can be effective, and this study 
reports that it is feasible to help a clinically relevant part 
of this vulnerable subgroup of smokers; however, these 
individuals have a lower quit rate than smokers without 
an SMD. More evidence is needed concerning the treat-
ment of competing addictions and dual diagnoses.
COnClusIOn
Only 28% of the smokers with an SMD successfully 
quit smoking which is significantly lower than the rate 
observed among smokers without an SMD (38%). The 
lowest quit rates were observed among patients with dual 
diagnoses, and the most important predictor of successful 
quitting was compliance.
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